{Reference Type}: Journal Article
{Title}: Early response to Tezepelumab in type-2 severe asthma patients non-responders to other biological treatments: a real-life study.
{Author}: Jiménez-Gómez M;Díaz-Campos RM;Gimeno-Díaz-De-Atauri Á;Fernández-Rodríguez C;Fernández-Crespo J;García-Moguel I;
{Journal}: J Asthma
{Volume}: 0
{Issue}: 0
{Year}: 2024 May 9
暂无{DOI}: 10.1080/02770903.2024.2349605
{Abstract}: <B>UNASSIGNED: </B>Biologic therapies play a crucial role in the treatment of severe asthma. Tezepelumab, a human monoclonal antibody (mAb), inhibits thymic stromal lymphopoietin, a pivotal factor in the pathophysiology of asthma. Although randomized clinical trials have demonstrated the efficacy of Tezepelumab, evidence gaps remain in real-world scenarios.<BR><B>UNASSIGNED: </B>We sought investigate Tezepelumab's response in a clinical setting, focusing on patients who previously failed to other asthma mAbs.<BR><B>UNASSIGNED: </B>Real-life study with severe uncontrolled asthma patients despite mAb treatment, requiring a switch to Tezepelumab. Follow-up was done four to six months after initiation of Tezepelumab. The primary endpoint was to evaluate the response in patients with poor response or intolerance to other mAbs.<BR><B>UNASSIGNED: </B>Nine patients were followed up during 7 months. Patients were predominantly middle-aged females with eosinophilic or eosinophilic-allergic phenotypes. Patients had a median failure rate of 2 mAbs (IQR 2-3), with an uncontrolled asthma (median of 2 severe exacerbations the previous year, airflow obstruction and 78% corticosteroid dependence). Tezepelumab demonstrated after 4 to 6 months of treatment reduce corticosteroid dependence (complete withdrawal in 2/7 patients), no exacerbations in 6/9, symptoms control improvement (Asthma Control Test score improved in 5/9) and modulate lung function (improving in 3/9 patients). These findings align with clinical trial results, suggesting Tezepelumab's potential in real-world settings.<BR><B>UNASSIGNED: </B>In real-world scenarios, despite the study's limitations, our results underscore Tezepelumab's promise as a therapeutic option for uncontrolled severe asthma, and may be useful for non-responders to other mAbs. Further studies are needed to corroborate these findings.